Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 + HRS-5041 in advanced prostate cancer
NCT07115446Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Bivalent/Multivalent Binders, Antibody-Drug Conjugates (ADCs), PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risvutatug rezetecan and HRS-5041 in prostate cancer (PCa), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose or Maximum Administrated Dose at 21 days. Started Aug 2025; status: recruiting.
02
Drugs
risvutatug rezetecanHRS-5041
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07115446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115446.